Genticel to Evaluate Roche Molecular Systems’ cobas® HPV Test in Preparation for Phase 3 Program of GTL001
07 janv. 2016 08h00 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Appoints Remi Palmantier, PhD, as Chief Scientific Officer to Accelerate Its Development
05 janv. 2016 16h01 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Announces First Patient Treated in U.S. Phase 1 Clinical Trial of GTL001, Company's Therapeutic Vaccine Candidate against HPV 16/18 Infections
29 oct. 2015 16h01 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Genticel Presents First Half 2015 Financial Results, Operational Progress & Outlook
21 sept. 2015 16h01 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of...
US Patent Granted for Use of Genticel's Antigen Delivery Vectors in Combination Therapy to Treat Cancer
08 sept. 2015 07h30 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, Sept. 8, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
Independent Data Safety Monitoring Board Recommends Continuation per Protocol of Genticel's Phase 2 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate
07 juil. 2015 16h05 HE
|
Genticel S.A.
Half of the 236 vaccinated patients have reached the 12-month follow-up milestone
Patient and physician engagement remains very strong with 98% retention rate*
PARIS and TOULOUSE, France,...
Genticel Receives FDA Clearance of IND Application for US Phase 1 Clinical Trial of GTL001 (ProCervix), Company's First-in-Class HPV Therapeutic Vaccine Candidate
16 juin 2015 08h00 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, June 16, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...
Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, Its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform
01 juin 2015 08h00 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, June 1, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...
Genticel to Present Further Promising Pharmacology In-Vivo Results of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (ProCervix), at AACR Annual Meeting 2015
20 avr. 2015 13h00 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, April 20, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...
Genticel Strengthens Management Team and Appoints Valerie Leroy as Senior Director, Corporate Communications and Investor Relations
09 avr. 2015 16h58 HE
|
Genticel S.A.
PARIS and TOULOUSE, France, April 9, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...